Acadia Pharmaceuticals (ACAD) Equity Ratio: 2009-2025
Historic Equity Ratio for Acadia Pharmaceuticals (ACAD) over the last 15 years, with Sep 2025 value amounting to 0.69.
- Acadia Pharmaceuticals' Equity Ratio rose 16.66% to 0.69 in Q3 2025 from the same period last year, while for Sep 2025 it was 0.69, marking a year-over-year increase of 16.66%. This contributed to the annual value of 0.62 for FY2024, which is 7.02% up from last year.
- According to the latest figures from Q3 2025, Acadia Pharmaceuticals' Equity Ratio is 0.69, which was up 2.72% from 0.67 recorded in Q2 2025.
- In the past 5 years, Acadia Pharmaceuticals' Equity Ratio registered a high of 0.79 during Q3 2021, and its lowest value of 0.54 during Q1 2024.
- Over the past 3 years, Acadia Pharmaceuticals' median Equity Ratio value was 0.59 (recorded in 2024), while the average stood at 0.61.
- Its Equity Ratio has fluctuated over the past 5 years, first declined by 19.85% in 2023, then increased by 24.53% in 2025.
- Acadia Pharmaceuticals' Equity Ratio (Quarterly) stood at 0.77 in 2021, then decreased by 11.83% to 0.68 in 2022, then decreased by 15.37% to 0.58 in 2023, then climbed by 7.02% to 0.62 in 2024, then rose by 16.66% to 0.69 in 2025.
- Its last three reported values are 0.69 in Q3 2025, 0.67 for Q2 2025, and 0.68 during Q1 2025.